The development pipeline
Merging global experience and technology to offer patients a brighter future
To promote our network-based drug discovery and global R&D efforts, Santen is placing significant emphasis on strengthening our relationships with universities, research organisations and other pharmaceutical firms to conceive new treatments for patients around the world. We hope such relationships will lead to the discovery and launch of novel therapies for severe dry eye disease, glaucoma, diabetic macular oedema and uveitis, a condition with limited treatment options.
Pipeline of prescription pharmaceuticals (clinical stage) As of October 2019
Filter indication
An intravitreal injection with immunosuppressive effect, anti-angiogenic effect, etc. Started an additional Phase 3 in December 2018 in the U.S. NDA filed in April 2015 in Asia.
A fixed dose combination drug of a prostaglandin F2α derivative and a beta-adrenergic receptor blocker. Launched in Japan in November 2014. Launched successively in European countries since January 2015. Launched successively in Asian countries since April 2016. Started Phase 3 in January 2019 in China.
• Ocular hypertension
An H1 receptor antagonist with membrane-stabilising function, as treatment for allergic conjunctivitis. High dose drug. Received manufacturing and marketing approval in September 2019 in Japan.
An EP2 receptor agonist with a new mechanism of action. Started Phase 3 in September 2018 in the U.S. Launched in November 2018 in Japan. Filed for marketing approval in Korea in April 2019 with successive filings in Asian countries.
• Ocular hypertension
A prostaglandin analogue eye drop drug product with a novel mode of action that is both FP and EP3 receptors dual agonist for the treatment of glaucoma and ocular hypertension. Started Phase 2b in July 2017 in the U.S. and Japan.
• Ocular hypertension
Muscarinic antagonist which reduces juvenile myopia progression. Started Phase 2/3 in August in Japan. Started Phase 2 in November 2017 in Asia.
In August 2016, Santen acquired InnFocus, developer of PRESERFLO™ MicroShunt*, a drainage implant device designed to lower and sustain intraocular pressure (IOP) for the treatment of primary open-angle glaucoma through the drainage of aqueous humour. Conducting Phase 2/3 in the U.S. and Europe in advance of application to FDA in the U.S. Received CE Mark in Europe.
*PRESERFLO™ is the new trademark of Innfocus MicroShunt®. PRESERFLO™ MicroShunt will replace Innfocus MicroShunt® in the future.
An ophthalmic emulsion which improves vernal keratoconjunctivitis by immunosuppressive effect. Cationic emulsion technology has enhanced ocular tissue penetration. Received the Marketing Authorisation Application approval from the European Commission Agency in July 2018 and launched in October 2018 in U.K. Received approval of expanded indication to Ikervis in August 2019 in Taiwan. Received marketing approval in December 2018 in Canada.
An ophthalmic emulsion of a prostaglandin F2α derivative, for the treatment of glaucoma and ocular hypertension. Started Phase 3 in April 2019 in Europe and Asia.
• Ocular hypertension
A toric intraocular lens for correcting astigmatism, which be implanted into an aphakia after cataract surgery. Filed for manufacturing and marketing approval in May 2019 in Japan.
Changes from Q1 FY19 (1 August, 2019)
| Dev. code | Changes |
|---|---|
| DE-114A | Received manufacturing and marketing approval in September 2019 in Japan. |
| DE-127 | Started Phase 2/3 in August 2019 in Japan. |
| DE-067C | Received marketing approval in August 2019 in Taiwan. |
Santen discloses the information on the ongoing clinical studies to confirm safety and efficacy of our drugs on the websites as below.
